论文部分内容阅读
目的探讨非小细胞肺癌(NSCLC)患者肿瘤组织内核苷酸切除修复交叉互补基因1(ERCC1)表达与吉西他滨联合顺铂(GP方案)化疗疗效的相关性。方法采用免疫组化S-P法检测51例Ⅱb～Ⅳ期NSCLC患者肿瘤组织内ERCC1的表达。所有患者接受至少2个周期以上的GP方案化疗,对患者化疗后的中位生存期(MST)及化疗后反应率(RR)进行评估。结果 51例患者ERCC1的阳性表达率为43.14%(22/51)。ERCC1表达阳性组化疗后的RR和MST分别为50.0%、17个月,与阴性组RR(31.04%)、MST(12个月)比较,差异无统计学意义(χ2=1.8877,P=0.1695;χ2=1.6767,P=0.1954)。结论 ERCC1表达阳性的NSCLC患者能从吉西他滨联合顺铂的化疗中受益,调控ERCC1表达逆转耐药的策略,将为肿瘤治疗带来新的方法和途径。
Objective To investigate the relationship between the expression of ERCC1 in patients with non-small cell lung cancer (NSCLC) and the efficacy of gemcitabine combined with cisplatin (GP regimen) chemotherapy. Methods The expression of ERCC1 in 51 patients with stage Ⅱb-Ⅳ NSCLC was detected by immunohistochemical S-P method. All patients underwent at least 2 cycles of GP regimen chemotherapy to assess their median survival (MST) and post-chemotherapy response (RR). Results The positive rate of ERCC1 in 51 patients was 43.14% (22/51). The RR and MST of patients with positive ERCC1 expression after chemotherapy were 50.0% and 17 months, respectively, which were not significantly different from those of negative patients (31.04% and MST 12 months) (χ2 = 1.8877, P = 0.1695; χ2 = 1.6767, P = 0.1954). Conclusion NSCLC patients with positive expression of ERCC1 can benefit from chemotherapy with gemcitabine combined with cisplatin. The strategy of reversing drug resistance by regulating the expression of ERCC1 will bring new methods and approaches for the treatment of cancer.